Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.

[1]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[2]  Qiongqing Wang,et al.  Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. , 2012, Cancer research.

[3]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[4]  J. Allanson,et al.  Cardio‐facio‐cutaneous syndrome: Does genotype predict phenotype? , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[5]  B. Gelb,et al.  Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[6]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[7]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[8]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[9]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[10]  D. Morrison,et al.  Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.

[11]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[12]  Michael Kracht,et al.  Peptides as signaling inhibitors for mammalian MAP kinase cascades. , 2009, Current pharmaceutical design.

[13]  Michael J Ackerman,et al.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.

[14]  Pablo Rodriguez-Viciana,et al.  Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.

[15]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[16]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[17]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[18]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[19]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[20]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[21]  C. Marshall,et al.  Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.

[22]  C. Pritchard,et al.  Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells , 1995, Molecular and cellular biology.

[23]  T. Brummer,et al.  Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. , 2012, Critical reviews in oncogenesis.

[24]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.